1. 1) Neelapu, S.S., Jacobson, C.A., Ghobadi, A., Miklos, D.B., Lekakis, L.J., Oluwole, O.O. et al. (2023) Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307-2315.
2. 2) Imai, K., Ng, A.K. and Ferrone, S. (1981) Characterization of monoclonal antibodies to human melanoma-associated antigens. J. Natl. Cancer Inst. 66, 489-496.
3. 3) Mittelman, A., Chen, Z.J., Yang, H., Wong, G.Y. and Ferrone, S. (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. U.S.A. 89, 466-470.
4. 4) Wang, X., Osada, T., Wang, Y., Yu, L., Sakakura, K., Katayama, A. et al. (2010) CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J. Natl. Cancer Inst. 102, 1496-1512.
5. 5) Whiteside, T. and Zarour, H.M. (2023) In memoriam: Soldano Ferrone, MD, PhD (1940-2023). J. Immunother. Cancer 11, e006761.